logo
  

Abiomed To Be Bought By Johnson & Johnson In $16.6 Bln Deal; Stock Surges In Pre-market

Drug major Johnson & Johnson (JNJ) Tuesday said it has entered into a definitive agreement to acquire Abiomed Inc. (ABMD), a provider of cardiovascular medical technology, for an upfront payment of $380.00 per share in cash.

In pre-market activity on Nasdaq, Abiomed shares were gaining around 51 percent to trade at $381.60.

The enterprise value of the acquisition is approximately $16.6 billion which includes cash acquired.

Abiomed shareholders will also receive a non-tradeable contingent value right or CVR entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.

Under the deal terms, a unit of Johnson & Johnson will commence a tender offer for all outstanding shares of Abiomed.

The transaction was unanimously approved by both companies' boards of directors, and the completion is expected prior to the end of the first quarter of 2023.

Johnson & Johnson expects to fund the transaction through a combination of cash on hand and short-term financing.

Following the completion of the deal, Abiomed will operate as a standalone business within Johnson & Johnson MedTech, becoming one of 12 JJMT priority platforms as defined by annual sales of at least $1 billion each.

The deal is expected to broaden Johnson & Johnson MedTech's position as a growing cardiovascular innovator.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Precision care innovator GE HealthCare Technologies, Inc., recently spun-off from General Electric Co., reported on Monday that profit for the fourth quarter declined from last year, reflecting higher interest and other financial charges. The company also initiated adjusted earnings guidance for the full-year 2023. Japanese auto major Toyota Motor Corp. has retained its title as the world's top selling automaker in fiscal 2022 for the third straight year, by selling around 10.5 million vehicles. The global sales were nearly flat with last year amid solid demand centered around Asia, while global production grew with increased capacity and production optimization in North America and Asia. Dutch consumer electronics giant Philips Electronics NV reported Monday a loss in its fourth quarter, compared to prior year's profit, even as sales increased. The company further declared a dividend, and said its order book remains strong. Going ahead, the company projects comparable sales growth in fiscal 2023, 2025, and beyond.
Follow RTT